Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease
<p>Abstract</p> <p>Background</p> <p>Intravenous immunoglobulin (IVIg) treatment results in an effective response from patients with acute-phase Kawasaki disease (KD), but 16.5% of them remain nonresponsive to IVIg. To address this therapeutic challenge, we tried a new...
Wedi'i Gadw mewn:
Prif Awduron: | Ohno Naohito (Awdur), Nagi-Miura Noriko (Awdur), Yamada Hitomi (Awdur), Yokouchi Yuki (Awdur), Nagao Tomokazu (Awdur), Oharaseki Toshiaki (Awdur), Takahashi Kei (Awdur), Saji Tsutomu (Awdur), Okazaki Tomio (Awdur), Suzuki Kazuo (Awdur) |
---|---|
Fformat: | Llyfr |
Cyhoeddwyd: |
BMC,
2011-09-01T00:00:00Z.
|
Pynciau: | |
Mynediad Ar-lein: | Connect to this object online. |
Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Eitemau Tebyg
-
Beneficial effects of anti-apolipoprotein A-2 on an animal model for coronary arteritis in Kawasaki disease
gan: Fuyu Ito, et al.
Cyhoeddwyd: (2022) -
Chronopharmacology of Mizoribine in Collagen-Induced Arthritis Rats
gan: Yuko Kanasaki, et al.
Cyhoeddwyd: (2012) -
Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics
gan: Teruo Murakami, et al.
Cyhoeddwyd: (2012) -
Efficacy and safety of adding mizoribine to standard treatment in patients with immunoglobulin A nephropathy: A randomized controlled trial
gan: Keiji Hirai, et al.
Cyhoeddwyd: (2017) -
Leukocyte activation by (1→3)-β-D glucans
gan: Yoshiyuki Adachi, et al.
Cyhoeddwyd: (1997)